Bridging the Gap Between Preclinical and Clinical Evaluation of Therapeutic Candidates

Session 4

Neuropsychiatric Genetics and Pharmacogenetics

David B. Goldstein, Ph.D.
Duke University

Many clinical challenges remain in the treatment of many neuropsychiatric conditions. Here I discuss the potential role of genetics and pharmacogenetics in helping to address some of these challenges, focusing particular attention on the treatment of schizophrenia and epilepsy. I concentrate attention on the results of two whole genome association study focussed on the identification of new drug targets and on predictors of adverse reactions.

Up to Top